Furthermore, PD-L1 expression—a key biomarker for ICI efficacy—appears to be upregulated in COPD-associated NSCLC, which may partly explain the improved response to ICIs observed in our meta-analysis [41, 42]. The gene discussed is CD274; the disease is chronic obstructive pulmonary disease.